← BackSanara MedTech Inc. · Orthopedic, Prosthetic & Surgical Appliances & SuppliesSMTI
Moderate riskNext report: Around Nov 11 (est.)
The short versionA profitable company with steady sales. Institutions are adding.
Going well
- Profitable, keeps 36% of sales as profit
- Sales up 19% last year
- Brings in more cash than it spends
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 20% to their holdings in the quarter ending June 2026 (49 bought, 19 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$33.01+0.6% that day
- Company value
- $303M
- Share price times all shares
- Price vs sales
- 2.8x
- No profit over the last year, so this compares value with sales instead
- Cash vs value
- 5%
- Cash as a share of company value
- Debt vs value
- 15%
- Debt as a share of company value
From SMTI's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$28.1M+9.0% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $109.8M, up 13% from the 12 months before. Over 5 years, sales grew about 46% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.165.7%
- MissDebt under half of equityNot relying on borrowed money.7.74x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.36.4%
- MissProfitable every yearSteady profits, not one good year.4 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$2.2M
- MissShare count not growingNot diluting owners. Falling means buybacks.+9.1% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.92.7%
- Revenue
- $103.1M
- +19.0% vs prior year
- 5-year growth
- +45.9%/yr
- revenue, per year
- Total debt
- $46.0M
- 7.74x equity
- Current ratio
- 1.80x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $28.1M
- +9.0% YoY
- EPS
- -$0.05
- vs -$0.23
- Op. margin
- 6.3%
- -3.3 pts
- Gross margin
- 93.0%
- +0.5 pts
- Free cash flow
- $2.0M
- Share count
- -3.0%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 2.3
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+19.7%Institutions added 19.7% to their holdings. 49 bought, 19 sold.
Shares held by institutions1.8M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+2.6%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
5.8x · $46.5M debtShares outstandingLatest reported
9MWhy moderate risk- Losing money, losses are large next to sales
- High debt: 5.85x equity
Next reportAround Nov 11 (est.)Estimated from the same quarter last year
- Results filedAug 11
- Results filedMay 11
- Results filedMar 24
- Results filedJan 23
- Results filedNov 12, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.